Novel adjuvants for induction of T-cell and antibody responses to encephalitogenic and regulatory determinants in Lewis rats

Vaccine

Volumn 16, Issue 1, 1998, Pages 99-108

  Ariail, Kiley S ^a   Bebo, Bruce F ^c   Adlard, Kirsten ^a   Robey, Ian ^a   Burrows, Gregory ^c   Newman, Mark J ^b   Todd, Charles W ^b   Vandenbark, Arthur A ^c   Offner, Halina ^c  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b Vaxcel Inc   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

COPOLYMER; IMMUNOLOGICAL ADJUVANT; MYELIN BASIC PROTEIN;

ADJUVANT THERAPY; ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; DRUG THERAPY; ETIOLOGY; FEMALE; IMMUNITY; IMMUNIZATION; NONHUMAN; PRIORITY JOURNAL; RAT; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; FEMALE; HYPERSENSITIVITY; LYMPH NODES; MYELIN BASIC PROTEINS; POLYMERS; RATS; RATS, INBRED LEW; T-LYMPHOCYTES;

EID: 0031986362     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(97)00150-3     Document Type: Article

References (31)

1. Manetti R., Parronchi P., Guidizi M.G., Piccinni M.-P., Maggi E., Trinchieri G., Romagnani S. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J. Exp. Med. 177:1993;1199-1204.
2. Seder R.A., Gazzinelli R.T., Sher A., Paul W.E. Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon γ production and diminishes interleukin 4 inhibition of such priming. Proc. Natl. Acad. Sci. USA. 90:1993;10188-10192.
3. Seder R.A., Paul W.E. Acquisition of lymphokine-producing phenotype by CD4+ T cells. Ann. Rev. Immunol. 12:1994;635-673.
4. Swain S.L., Weinberg A.D., English M., Huston G. IL-4 directs the development of Th2-like helper effectors. J. Immunol. 145:1990;3796-3806.
5. Alvord, E.C. In Experimental Allergic Encephalomyelitis: A Useful Model for Multiple Sclerosis, ed. E.C. Alvord, M.W. Kies and A.J. Suckling, Alan R. Liss, Inc., New York, 1984, pp. 523-537.
6. Tuohy V.K., Lu Z., Sobel R.A., Laursen R.A., Lees M.B. Identification of an encephalitogenic determinant of myelin proteolipid protein for SJL mice. J. Immunol. 142:1989;1523-1527.
7. Whitham R.H., Jones R.E., Hashim G.A., Hoy C.M., Wang R.-Y., Vandenbark A.A., Offner H. Location of a new encephalitogenic epitope (residues 43-64) in proteolipid protein which induces relapsing EAE in PL/J and (SJL×PL)F1 mice. J. Immunol. 147:1991;3803-3808.
8. Fritz R.B., Chou C.-H.J., McFarlin D.E. Induction of experimental allergic encephalomyelitis in PL/J and (SJL/J×PL/J)F1 mice by myelin basic protein and its peptides: localization of a second encephalitogenic determinant. J. Immunol. 130:1983;191-194.
9. Burns F.R., Li X., Shen N., Offner H., Chou Y., Vandenbark A.A., Heber-Katz E. Both rat and mouse T cell receptors specific for the encephalitogenic determinant of myelin basic protein use similar Vα and Vβ chain genes even though the major histocompatibility complex and encephalitogenic determinants being recognized are different. J. Exp. Med. 169:1989;27-39.
10. Urban J.L., Kumar V., Kono D.H., Gomez C., Horvath S.J., Clayton J., Ando D.G., Sercarz E.E., Hood L. Restricted use of T cell receptor V genes in murine autoimmune encephalomyelitis raises possibilities for antibody therapy. Cell. 54:1988;577-581.
11. Kotzin B.L., Karuturi S., Chou Y.K., Lafferty J., Forrester J.M., Better M., Nedwin G.E., Offner H., Vandenbark A.A. Preferential T cell receptor β-chain variable gene use in myelin basic protein-reactive T cell clones from patients with multiple sclerosis. Proc. Natl. Acad. Sci. USA. 88:1991;9161-9165.
12. Offner H., Hashim G.A., Vandenbark A.A. T cell receptor peptide therapy triggers autoregulation of experimental encephalomyelitis. Science. 251:1991;430-432.
13. Vandenbark A.A., Hashim G.A., Offner H. Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis. Nature. 341:1989;541-544.
14. Vandenbark A.A., Hashim G.A., Offner H. T cell receptor peptides in treatment of autoimmune disease: Rationale and potential. J. Neurosci. Res. 43:1996;391-402.
15. Offner H., Vainiene M., Celnik B., Weinberg A.D., Buenafe A., Vandenbark A.A. Co-culture of TCR peptide-specific T cells with basic protein-specific T cells inhibits proliferation, IL-3 mRNA and transfer of experimental autoimmune encephalomyelitis. J. Immunol. 153:1994;4988-4996.
16. Vandenbark A.A., Chou Y.K., Whitham R., Mass M., Buenafe A., Liefeld D., Kavanagh D., Cooper S., Hashim G.A., Offner H., Bourdette D.N. Treatment of multiple sclerosis with T cell receptor peptides: Results of a double-blind pilot trial. Nature Med. 2:1996;1109-1115.
17. Howerton D.A., Hunter R.L., Ziegler H.K., Check I.J. The induction of macrophage Ia expression in vivo by synthetic copolymer L81. J. Immunol. 144:1990;1578-1584.
18. Hunter R.L., Bennett B. The adjuvant activity of nonionic block polymer surfactants. II. Antibody formation and inflammation related to the structure of triblocks and octablock copolymers. J. Immunol. 133:1984;3167-3175.
19. Hunter R.L., McNicholl J., Lal A.A. Mechanisms of action of nonionic block copolymer adjuvants. AIDS Res. Hum. Retroviruses. 2:1994;S95-S98.
20. Hunter R.L., Bennett B. The adjuvant activity of nonionic block polymer surfactants. III. Characterization of selected biologically active surfaces. Scand. J. Immunol. 23:1986;287-300.
21. Hunter R.L., Strickland F., Kezdy F. Studies on the adjuvant activity of nonionic block polymer surfactants. I. The role of hydrophile-lipophile balance. J. Immunol. 127:1981;1244-1250.
22. Todd, C.W., Pozzi, L.A.M., Guarnaccia, J.R., Balasubramanian, M., Henk, W.G., Younger, L.E. and Newman, M.J. Development of an adjuvant-active nonionic block copolymer for use in oil-free subunit vaccine formulations. Vaccine 1996, in press.
23. Eylar E.H., Brostoff S.W., Hashim G.A., Caccam J., Bernett P. Basic A1 protein of the myelin membrane: The complete amino acid sequence. J. Biol. Chem. 246:1971;5770-5784.
24. Hashim G.A., Day E.D., Fredane L., Intintola P., Carvalho E. Biological activity of region 65 to 102 of the myelin basic protein. J. Neurosci. Res. 16:1986;467-478.
25. Vainiene M., Burrows G.G., Ariail K., Robey I., Vandenbark A.A., Offner H. Neonatal injection of Lewis rats with recombinant Vβ8.2 induces T cell but not B cell tolerance and increased severity of experimental autoimmune encephalomyelitis. J. Neurosci. Res. 45:1996;475-486.
26. Vandenbark A.A., Gill T., Offner H. A myelin basic protein specific T lymphocyte line that mediates experimental autoimmune encephalomyelitis. J. Immunol. 135:1985;223-228.
27. Bourdette D.N., Vainiene M., Morrison W.J., Jones R., Turner J., Hashim G.A., Vandenbark A.A., Offner H. Myelin basic protein specific T cell lines and clones derived from the central nervous system of rats with experimental autoimmune encephalomyelitis only recognize encephalitogenic epitopes. J. Neurosci. Res. 30:1991;308-315.
28. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:1987;156-159.
29. Offner H., Brostoff S.W., Vandenbark A.A. Antibodies against I-A and I-E determinants inhibit the activation and function of encephalitogenic T-lymphocyte lines. Cell. Immunol. 100:1986;364-373.
30. Hashim G., Vandenbark A.A., Galang A.B., Diamanduros T., Carvalho E., Srinivasan J., Jones R., Vainiene M., Morrison W.J., Offner H. Antibodies specific for a Vβ8 T cell receptor peptide suppress experimental autoimmune encephalomyelitis. J. Immunol. 144:1990;4621-4627.
31. Newman, M.J., Guarnaccia, J.R., Pozzi, L.A.M. and Todd, C.W. Rational design and characterization of adjuvant-active synthetic block copolymers. In Vaccines: New Technologies and Applications, IBC Biomedical Library, Cambridge, MA, 1996.